Ernexa Therapeutics Inc. (ERNA) Stock Profile — Insider Trades & Financials

Net Income-$1.5M

EPS$-2.23

Market Cap$6.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Sanjeev Luther

CEO & Executive Director

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The companyâs lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Founded: 2018
Employees: 7
Headquarters: Cambridge, Massachusetts, United States

⚡

Core Efficiency

ROE?

-62.56%

ROA?

-25.75%

D/E Ratio?

1.43

📊

Profitability Ratios

Current Ratio?

1.01

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 11, 2026 (in 124 days)

Annual Report (10-K) — Based on filing pattern

Aug 11, 2026

Predicted10-K

Mar 13, 2026

10-KQ4 20251d after period end

Nov 7, 2025

10-QQ3 20250d after period end

Aug 13, 2025

10-QQ2 20251d after period end

May 7, 2025

10-QQ1 20250d after period end

Mar 12, 2025

10-KQ4 20242d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Aug 13, 2024

10-QQ2 20244d after period end

May 14, 2024

10-QQ1 20241d after period end

Loading company sections...

Ernexa Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness